Professor Leszek Lisowski is a molecular biologist and vectorologist by training and is globally recognized for his contributions to the field of Adeno-Associated Virus (AAV) vector bioengineering. He developed the first bioengineered AAV to enter liver clinical trials and has since developed multiple novel AAVs that have entered clinical evaluation across a variety of clinical targets.

In recent years, he became directly involved in clinical-grade AAV manufacturing and established the first Australian AAV cGMP-grade vector manufacturing facility, which he leads in his capacity as Chief Technology Officer (CTO). He has also been actively engaged in the translation and commercialization of AAV-based gene therapies for the treatment of genetic disorders. He has co-founded five gene therapy companies and is a co-founder and President of a US-based foundation dedicated to the development of gene therapies for rare genetic disorders.